Annual revenue on the filings was KRW 34.2 billion in 2022, KRW 34 billion in 2023 (down 0.6%), KRW 35.7 billion in 2024 (up 4.8%) and KRW 34 billion in 2025 (down 4.8%), with 2024 the largest year and 2025 the smallest in the period.
Operating results were an operating loss of KRW 4.78 billion in 2022 and KRW 3.35 billion in 2023, a continued loss with a narrower gap, before a turn to operating profit of KRW 1.41 billion in 2024. Operating profit then fell to KRW 917 million in 2025, down 34.7%.
The operating margin was -14.0% in 2022, -9.9% in 2023, 3.9% in 2024 and 2.7% in 2025. Net income attributable to controlling shareholders was a loss of KRW 3.44 billion in 2022 and a loss of KRW 6.3 billion in 2023, which widened the loss, before turning to a profit of KRW 646 million in 2024.
It rose to KRW 1.01 billion in 2025, up 56.0%, moving in the opposite direction from operating profit. Quarterly revenue went from KRW 3.94 billion in Q3 2025 to KRW 7.66 billion in Q4 2025 (up 94.7% from the prior quarter) and peaked at KRW 14.1 billion in Q1 2026.
Operating profit turned positive at KRW 3.13 billion in Q1 2026, but Q2 2026 operating profit was only KRW 172 million (down 94.5% from the prior quarter).
In Q3 2026, revenue was KRW 4.23 billion (down 59.5% from the prior quarter, up 7.5% year on year) and operating loss was KRW 1.93 billion, a switch to loss and a wider loss year on year.
Net loss attributable to controlling shareholders was KRW 1.5 billion in Q3 2026, the second straight quarter of losses since Q2 2026.
For Q1 2026, a WiseReport company summary said revenue rose slightly on steady sales of core product lines, while operating profit eased slightly on higher costs for formulation products and new drug development.